nirmatrelvir ritonavir
Selected indexed studies
- Nirmatrelvir Plus Ritonavir: First Approval. (Drugs, 2022) [PMID:35305258]
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? (Biomed Pharmacother, 2023) [PMID:37018987]
- Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews. (J Antimicrob Chemother, 2024) [PMID:38084876]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirmatrelvir Plus Ritonavir: First Approval. (2022) pubmed
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy? (2023) pubmed
- Nirmatrelvir/ritonavir for COVID-19: an overview of systematic reviews. (2024) pubmed
- Nirmatrelvir and ritonavir. (2024) pubmed
- Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19. (2024) pubmed
- Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. (2023) pubmed
- Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. (2022) pubmed
- Paxlovid (nirmatrelvir/ritonavir). (2022) pubmed
- Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19. (2023) pubmed
- Nirmatrelvir-ritonavir for COVID-19. (2022) pubmed